• Je něco špatně v tomto záznamu ?

Expression, Epigenetic, and Genetic Changes of HNF1B in Colorectal Lesions: an Analysis of 145 Cases

M. Bártů, J. Hojný, N. Hájková, R. Michálková, E. Krkavcová, K. Simon, V. Frýba, I. Stružinská, K. Němejcová, P. Dundr

. 2020 ; 26 (4) : 2337-2350. [pub] 20200601

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026543

Grantová podpora
AZV 17-28404A Ministerstvo Zdravotnictví Ceské Republiky
RVO64165 Ministerstvo Zdravotnictví Ceské Republiky
Progress Q28/LF1 Univerzita Karlova v Praze
SVV 260367 Univerzita Karlova v Praze (CZ)
CZ.02.1.01/0.0/0.0/18_046/0015959 European Regional Development Fund
BBMRI_CZ LM2018125 European Regional Development Fund
OPPK CZ.2.16/3.1.00/24509 European Regional Development Fund
NV17-28404A MZ0 CEP - Centrální evidence projektů

Hepatocyte nuclear factor 1 beta (HNF1B) is transcription factor which plays a crucial role in the regulation of the development of several organs, but also seems to be implicated in the development of certain tumours, especially the subset of clear cell carcinomas of the ovary and kidney. Depending on the type of the tumour, HNF1B may act as either a tumour suppressor or an oncogene, although the exact mechanism by which HNF1B participates in the process of cancerogenesis is unknown. Using immunohistochemical approach and methylation and mutation analysis, we have investigated the expression, epigenetic, and genetic changes of HNF1B on 40 cases of colorectal adenomas and 105 cases of colorectal carcinomas. The expression of HNF1B was correlated with the benign or malignant behaviour of the lesion, given that carcinomas showed significantly lower levels of expression compared to adenomas. In carcinomas, lower levels of HNF1B expression were associated with recurrence and shortened disease-free survival. The mutation analysis revealed three somatic mutations (two frameshift and one nonsense) in the carcinoma sample set. Promoter methylation was detected in three carcinomas. These results suggest that in colorectal cancer, HNF1B may play a part in the pathogenesis and act in a tumour suppressive fashion.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026543
003      
CZ-PrNML
005      
20211026132821.0
007      
ta
008      
211013s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12253-020-00830-2 $2 doi
035    __
$a (PubMed)32488808
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Bártů, Michaela $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
245    10
$a Expression, Epigenetic, and Genetic Changes of HNF1B in Colorectal Lesions: an Analysis of 145 Cases / $c M. Bártů, J. Hojný, N. Hájková, R. Michálková, E. Krkavcová, K. Simon, V. Frýba, I. Stružinská, K. Němejcová, P. Dundr
520    9_
$a Hepatocyte nuclear factor 1 beta (HNF1B) is transcription factor which plays a crucial role in the regulation of the development of several organs, but also seems to be implicated in the development of certain tumours, especially the subset of clear cell carcinomas of the ovary and kidney. Depending on the type of the tumour, HNF1B may act as either a tumour suppressor or an oncogene, although the exact mechanism by which HNF1B participates in the process of cancerogenesis is unknown. Using immunohistochemical approach and methylation and mutation analysis, we have investigated the expression, epigenetic, and genetic changes of HNF1B on 40 cases of colorectal adenomas and 105 cases of colorectal carcinomas. The expression of HNF1B was correlated with the benign or malignant behaviour of the lesion, given that carcinomas showed significantly lower levels of expression compared to adenomas. In carcinomas, lower levels of HNF1B expression were associated with recurrence and shortened disease-free survival. The mutation analysis revealed three somatic mutations (two frameshift and one nonsense) in the carcinoma sample set. Promoter methylation was detected in three carcinomas. These results suggest that in colorectal cancer, HNF1B may play a part in the pathogenesis and act in a tumour suppressive fashion.
650    _2
$a senioři $7 D000368
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a kolorektální nádory $x genetika $x metabolismus $x patologie $7 D015179
650    12
$a metylace DNA $7 D019175
650    12
$a epigeneze genetická $7 D044127
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    12
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a hepatocytární jaderný faktor 1-beta $x genetika $7 D051539
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lokální recidiva nádoru $x genetika $x metabolismus $x patologie $7 D009364
650    _2
$a prognóza $7 D011379
650    _2
$a promotorové oblasti (genetika) $7 D011401
650    _2
$a míra přežití $7 D015996
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hojný, Jan $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
700    1_
$a Hájková, Nikola $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
700    1_
$a Michálková, Romana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
700    1_
$a Krkavcová, Eva $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
700    1_
$a Simon, Karol $u First Faculty of Medicine, Charles University and General University Hospital in Prague, 12800, Prague, Czech Republic
700    1_
$a Frýba, Vladimír $u 1st Department of Surgery - Department of Abdominal, Thoracic Surgery and Traumatology, First Faculty of Medicine, Charles University and General University Hospital, 12808, Prague, Czech Republic
700    1_
$a Stružinská, Ivana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
700    1_
$a Němejcová, Kristýna $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
700    1_
$a Dundr, Pavel $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic. Pavel.Dundr@vfn.cz
773    0_
$w MED00180530 $t Pathology oncology research : POR $x 1532-2807 $g Roč. 26, č. 4 (2020), s. 2337-2350
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32488808 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132827 $b ABA008
999    __
$a ok $b bmc $g 1715310 $s 1147050
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 26 $c 4 $d 2337-2350 $e 20200601 $i 1532-2807 $m Pathology oncology research $n Pathol Oncol Res $x MED00180530
GRA    __
$a AZV 17-28404A $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a RVO64165 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a Progress Q28/LF1 $p Univerzita Karlova v Praze
GRA    __
$a SVV 260367 $p Univerzita Karlova v Praze (CZ)
GRA    __
$a CZ.02.1.01/0.0/0.0/18_046/0015959 $p European Regional Development Fund
GRA    __
$a BBMRI_CZ LM2018125 $p European Regional Development Fund
GRA    __
$a OPPK CZ.2.16/3.1.00/24509 $p European Regional Development Fund
GRA    __
$a NV17-28404A $p MZ0
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...